Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Wave Life Sciences USA, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05683860CT.gov Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) | — | Terminated | — | — | — |
NCT04931862CT.gov Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Wve-004 (this asset) | Wave Life Sciences USA, Inc. | P1/2 | CC · 45 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Riluzole | AB Science | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
| Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors | Brainstorm-Cell Therapeutics | P3 | BB |
| Mci-186 | Tanabe Pharma Corporation | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Other indications for Wve-004
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Frontotemporal Dementia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Wve-004 in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/wve-004-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →